Esperion Ebitda vs Reconciled Depreciation Analysis

ESPR Stock

USD 1.90 0.09 4.52%

Esperion Therapeutics financial indicator trend analysis is much more than just examining Esperion Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Esperion Therapeutics is a good investment. Please check the relationship between Esperion Therapeutics Ebitda and its Reconciled Depreciation accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

Ebitda vs Reconciled Depreciation

Ebitda vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Esperion Therapeutics Ebitda account and Reconciled Depreciation. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Esperion Therapeutics' Ebitda and Reconciled Depreciation is -0.58. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Esperion Therapeutics, assuming nothing else is changed. The correlation between historical values of Esperion Therapeutics' Ebitda and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Esperion Therapeutics are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Ebitda i.e., Esperion Therapeutics' Ebitda and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

-0.58

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Ebitda

Reconciled Depreciation

Most indicators from Esperion Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Esperion Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.As of 04/29/2024, Selling General Administrative is likely to drop to about 64.1 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 25.1 M

	2023	2024 (projected)
Interest Income	4.0M	3.5M
Reconciled Depreciation	250K	432.3K

Interest Income Reconciled Depreciation

Esperion Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Intangible Assets	Short Term Investments	Other Liab
Total Assets		0.3	0.51	0.4	-0.43	0.45	-0.01	-0.52	0.48	0.74	0.54	0.74	0.49	0.34	0.5	0.64	0.25	0.49	0.27	0.98	-0.18	0.39	-0.22	-0.4	0.43	-0.66
Short Long Term Debt Total	0.3		0.88	0.92	-0.5	0.68	0.91	-0.89	0.48	0.33	-0.24	0.33	0.91	0.93	0.91	0.31	0.18	0.93	0.73	0.37	0.78	0.95	0.44	-0.17	-0.38	-0.71
Other Current Liab	0.51	0.88		0.94	-0.79	0.66	0.68	-0.99	0.67	0.55	-0.25	0.55	0.94	0.87	0.95	0.46	0.25	0.97	0.61	0.62	0.48	0.9	0.35	-0.25	-0.24	-0.81
Total Current Liabilities	0.4	0.92	0.94		-0.64	0.75	0.76	-0.96	0.76	0.46	-0.32	0.46	0.89	0.92	0.88	0.32	0.26	0.92	0.78	0.51	0.66	0.91	0.32	-0.25	-0.28	-0.72
Total Stockholder Equity	-0.43	-0.5	-0.79	-0.64		-0.49	-0.22	0.75	-0.65	-0.68	0.38	-0.68	-0.59	-0.43	-0.77	-0.65	-0.19	-0.76	-0.29	-0.58	-0.02	-0.48	-0.48	0.16	0.32	0.53
Property Plant And Equipment Net	0.45	0.68	0.66	0.75	-0.49		0.39	-0.66	0.71	0.73	-0.26	0.73	0.52	0.57	0.71	0.39	0.24	0.73	0.94	0.55	0.43	0.55	0.42	0.0	-0.41	-0.45
Net Debt	-0.01	0.91	0.68	0.76	-0.22	0.39		-0.71	0.24	-0.1	-0.26	-0.1	0.8	0.87	0.69	0.01	0.15	0.72	0.55	0.02	0.89	0.88	0.31	-0.06	-0.31	-0.54
Retained Earnings	-0.52	-0.89	-0.99	-0.96	0.75	-0.66	-0.71		-0.7	-0.52	0.21	-0.51	-0.95	-0.9	-0.94	-0.45	-0.26	-0.96	-0.63	-0.62	-0.52	-0.92	-0.31	0.28	0.2	0.83
Accounts Payable	0.48	0.48	0.67	0.76	-0.65	0.71	0.24	-0.7		0.61	-0.29	0.6	0.51	0.54	0.55	0.33	0.24	0.61	0.65	0.6	0.2	0.49	0.09	-0.26	-0.09	-0.5
Cash	0.74	0.33	0.55	0.46	-0.68	0.73	-0.1	-0.52	0.61		0.03	1.0	0.36	0.23	0.6	0.7	0.1	0.59	0.5	0.82	-0.14	0.27	0.34	-0.27	-0.2	-0.47
Non Current Assets Total	0.54	-0.24	-0.25	-0.32	0.38	-0.26	-0.26	0.21	-0.29	0.03		0.03	-0.06	-0.18	-0.2	0.19	0.04	-0.23	-0.31	0.35	-0.34	-0.12	-0.51	-0.19	0.69	-0.16
Cash And Short Term Investments	0.74	0.33	0.55	0.46	-0.68	0.73	-0.1	-0.51	0.6	1.0	0.03		0.36	0.23	0.6	0.7	0.09	0.59	0.5	0.81	-0.14	0.27	0.34	-0.27	-0.2	-0.47
Common Stock Total Equity	0.49	0.91	0.94	0.89	-0.59	0.52	0.8	-0.95	0.51	0.36	-0.06	0.36		0.95	0.9	0.36	0.18	0.91	0.53	0.54	0.56	0.98	0.23	-0.29	-0.11	-0.89
Common Stock Shares Outstanding	0.34	0.93	0.87	0.92	-0.43	0.57	0.87	-0.9	0.54	0.23	-0.18	0.23	0.95		0.8	0.1	0.21	0.84	0.67	0.4	0.72	0.98	0.16	-0.25	-0.16	-0.79
Non Current Liabilities Total	0.5	0.91	0.95	0.88	-0.77	0.71	0.69	-0.94	0.55	0.6	-0.2	0.6	0.9	0.8		0.58	0.21	1.0	0.62	0.59	0.5	0.86	0.51	-0.2	-0.36	-0.76
Other Current Assets	0.64	0.31	0.46	0.32	-0.65	0.39	0.01	-0.45	0.33	0.7	0.19	0.7	0.36	0.1	0.58		0.14	0.54	0.13	0.66	-0.13	0.26	0.42	-0.16	-0.06	-0.43
Other Stockholder Equity	0.25	0.18	0.25	0.26	-0.19	0.24	0.15	-0.26	0.24	0.1	0.04	0.09	0.18	0.21	0.21	0.14		0.22	0.21	0.26	0.17	0.17	-0.1	0.07	0.2	-0.02
Total Liab	0.49	0.93	0.97	0.92	-0.76	0.73	0.72	-0.96	0.61	0.59	-0.23	0.59	0.91	0.84	1.0	0.54	0.22		0.67	0.59	0.55	0.89	0.48	-0.22	-0.35	-0.77
Property Plant And Equipment Gross	0.27	0.73	0.61	0.78	-0.29	0.94	0.55	-0.63	0.65	0.5	-0.31	0.5	0.53	0.67	0.62	0.13	0.21	0.67		0.36	0.63	0.62	0.34	-0.01	-0.41	-0.41
Total Current Assets	0.98	0.37	0.62	0.51	-0.58	0.55	0.02	-0.62	0.6	0.82	0.35	0.81	0.54	0.4	0.59	0.66	0.26	0.59	0.36		-0.14	0.43	-0.12	-0.4	0.32	-0.69
Short Term Debt	-0.18	0.78	0.48	0.66	-0.02	0.43	0.89	-0.52	0.2	-0.14	-0.34	-0.14	0.56	0.72	0.5	-0.13	0.17	0.55	0.63	-0.14		0.69	0.34	-0.16	-0.42	-0.25
Common Stock	0.39	0.95	0.9	0.91	-0.48	0.55	0.88	-0.92	0.49	0.27	-0.12	0.27	0.98	0.98	0.86	0.26	0.17	0.89	0.62	0.43	0.69		0.25	-0.25	-0.18	-0.84
Non Currrent Assets Other	-0.22	0.44	0.35	0.32	-0.48	0.42	0.31	-0.31	0.09	0.34	-0.51	0.34	0.23	0.16	0.51	0.42	-0.1	0.48	0.34	-0.12	0.34	0.25		0.19	-0.91	-0.09
Intangible Assets	-0.4	-0.17	-0.25	-0.25	0.16	0.0	-0.06	0.28	-0.26	-0.27	-0.19	-0.27	-0.29	-0.25	-0.2	-0.16	0.07	-0.22	-0.01	-0.4	-0.16	-0.25	0.19		-0.2	0.32
Short Term Investments	0.43	-0.38	-0.24	-0.28	0.32	-0.41	-0.31	0.2	-0.09	-0.2	0.69	-0.2	-0.11	-0.16	-0.36	-0.06	0.2	-0.35	-0.41	0.32	-0.42	-0.18	-0.91	-0.2		-0.07
Other Liab	-0.66	-0.71	-0.81	-0.72	0.53	-0.45	-0.54	0.83	-0.5	-0.47	-0.16	-0.47	-0.89	-0.79	-0.76	-0.43	-0.02	-0.77	-0.41	-0.69	-0.25	-0.84	-0.09	0.32	-0.07

Click cells to compare fundamentals

Esperion Therapeutics Account Relationship Matchups

Esperion Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	214.4M	353.3M	381.6M	247.9M	205.8M	181.9M
Other Current Liab	34.6M	37.8M	48.7M	65.4M	62.7M	65.9M
Total Current Liabilities	66.1M	94.1M	73.4M	92.3M	156.2M	164.0M
Total Stockholder Equity	(695.3M)	(838.8M)	(1.1B)	(1.3B)	(455.0M)	(432.2M)
Property Plant And Equipment Net	2.7M	7.3M	2.6M	1.2M	4.7M	4.9M
Net Debt	(164.6M)	(119.6M)	51.3M	136.2M	458.7M	481.6M
Retained Earnings	(695.3M)	(838.8M)	(1.1B)	(1.3B)	(1.5B)	(1.5B)
Accounts Payable	28.9M	52.0M	17.6M	23.0M	31.7M	33.3M
Cash	166.1M	305.0M	208.9M	124.8M	82.2M	91.3M
Non Current Assets Total	2.7M	7.4M	52.6M	1.3M	4.7M	4.5M
Cash And Short Term Investments	166.1M	305.0M	208.9M	124.8M	82.2M	91.8M
Common Stock Shares Outstanding	27.1M	27.5M	28.9M	66.4M	103.1M	108.3M
Liabilities And Stockholders Equity	(500.8M)	(389.4M)	(527.8M)	(768.3M)	205.8M	216.1M
Non Current Liabilities Total	128.4M	355.3M	505.2M	479.4M	504.6M	529.8M
Other Current Assets	10.9M	24.8M	62.8M	9.9M	4.7M	8.6M
Other Stockholder Equity	(50K)	(26K)	(30K)	(73K)	1.1B	1.1B
Total Liab	194.5M	449.4M	578.5M	571.7M	660.8M	693.8M
Property Plant And Equipment Gross	2.7M	7.3M	664K	164K	6.7M	7.0M
Total Current Assets	211.7M	345.9M	329.0M	246.7M	201.1M	160.4M
Accumulated Other Comprehensive Income	(845K)	(319K)	23K	0.0	(31K)	(2K)
Non Currrent Assets Other	(34.7M)	(7.4M)	50M	(42.1M)	(1.0)	(1.05)
Short Term Investments	165.7M	99.1M	34.7M	0.0	50.4M	42.1M
Property Plant Equipment	1.1M	1.3M	664K	164K	188.6K	179.2K
Net Tangible Assets	19.9M	(96.2M)	(196.9M)	(323.8M)	(291.4M)	(276.8M)
Retained Earnings Total Equity	(695.3M)	(838.8M)	(1.1B)	(1.3B)	(1.2B)	(1.1B)
Capital Surpluse	715.2M	797.7M	964.4M	1.1B	1.2B	676.3M
Long Term Investments	34.7M	0.0	50.4M	42.1M	37.9M	29.2M
Net Invested Capital	20.0M	83.2M	61.3M	(63.9M)	(193.4M)	(183.7M)

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Esperion Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Esperion Therapeutics' short interest history, or implied volatility extrapolated from Esperion Therapeutics options trading.

Pair Trading with Esperion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.

The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Esperion Therapeutics is a strong investment it is important to analyze Esperion Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Esperion Therapeutics' future performance. For an informed investment choice regarding Esperion Stock, refer to the following important reports:

How To Invest In Esperion

Details

Is Esperion Stock a good investment?

Details

What is Esperion Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Esperion Stock analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Commodity Directory Find actively traded commodities issued by global exchanges
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Money Managers Screen money managers from public funds and ETFs managed around the world

Is Esperion Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Esperion Therapeutics. If investors know Esperion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Esperion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.03)

Revenue Per Share

1.128

Quarterly Revenue Growth

0.714

Return On Assets

(0.43)

Return On Equity

(2.61)

The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Esperion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Esperion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Esperion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Esperion Ebitda vs Reconciled Depreciation Analysis

Ebitda vs Reconciled Depreciation

Ebitda vs Reconciled Depreciation Correlation Analysis

Correlation Coefficient

Ebitda

Reconciled Depreciation

Esperion Therapeutics fundamental ratios Correlations

Esperion Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Esperion Therapeutics fundamental ratios Accounts

Pair Trading with Esperion Therapeutics

Complementary Tools for Esperion Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 1.0	Non Current Liabilities Total
Total Current Assets	+ 0.98	Total Assets
Common Stock	+ 0.98	Common Stock Total Equity
Common Stock	+ 0.98	Common Stock Shares Outstanding
Total Liab	+ 0.97	Other Current Liab

Retained Earnings	- 0.99	Other Current Liab
Total Liab	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Common Stock Total Equity	- 0.95	Retained Earnings
Non Current Liabilities Total	- 0.94	Retained Earnings
Common Stock	- 0.92	Retained Earnings